Experts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.
Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma.
Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.
Every year, Huntsman Cancer Institute receives funding from the American Cancer Society to support the promising research of junior faculty.
Sarah Montini, BSN, RN, OCN, provides an in-depth look at abemaciclib for the treatment of patients with breast cancer in a downloadable reference sheet.
Experts share insights on standard work-up and staging practices for a patient with newly diagnosed bladder cancer.
Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP; and Rosaleen Bloom PhD, APRN, ACNS-BC, AOCNS, discuss the ways a cancer diagnosis can impair an individual’s ability to work normally.
Getting to the root of patients’ issues can provide support for their cancer journey through accessible means, says Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP.
Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell lung cancer.
The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.
Melanie Darvish, BSN, RN, shares her experience attending the Oncology Nursing Society (ONS) Congress with an ONS Scholarship.
David Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses findings indicating that patients with agitated delirium may be under-sedated, in accordance with their personalized sedation goal.
Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.
Early coordination with multiple specialty teams can maximize outcomes and improve quality of life for patients with complex metastatic disease.
Panelists discuss how treatment selection between lorlatinib and alectinib for ALK-positive non–small cell lung cancer (NSCLC) should consider both efficacy data favoring lorlatinib and patient-specific factors such as neuropsychiatric history or cardiovascular comorbidities that might favor alectinib.
Subcutaneous daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma, according to an expert.
Panelists discuss City of Hope’s multidisciplinary approach, highlighting pharmacists providing medication guidance, social workers offering emotional support, and palliative care specialists managing symptoms, while consultants such as cardiologists and infectious disease experts address specific health issues to ensure coordinated, personalized care; complementary therapies such as acupuncture and mindfulness help manage adverse effects like neuropathy, and support groups foster community and resilience among patients and caregivers throughout their myeloma journey.
A lung cancer screening navigator offers their perspective on shared decision-making.
The investigational BET inhibitor is being investigated combined with abemaciclib or cisplatin/etoposide in NUT carcinoma in 2 clinical trials.
Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.
Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.
Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.
Triple-negative breast cancer often occurs in women younger than 40.
Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.
This video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.
Brianna Lutz, MSN, RN, OCN, discusses a red-and-green dot hourly column that shows which patients with cancer have been attended to in the past hour.
Kelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.
Treatment with Temferon led to prolonged survival and possible disease control in 2 patients with newly diagnosed glioblastoma multiforme.
The gift is from the estate of Tom and Catherine Culley, longtime residents of the East Coast and worldwide travelers.